Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neutropenia

Neutropenia

Subtypes of Neutropenia

Febrile Neutropenia 2

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neutropenia

28 trials tracked for Neutropenia: 13 in phase 3 or 4 and 4 with published results. The most-cited published study has 108 citations.

28Trials tracked
13Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 11 Phase 2 10 Phase 1 3 Other / NA 2
  1. Phase 3 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed · 108 cited
  2. Phase 3 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Completed · 40 cited
  3. Phase 3 Study to Compare the Efficacy and Safety of F-627 and GRAN® Completed · 16 cited
  4. Phase 3 Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed · 10 cited
  5. Phase 4 Letermovir Use in Heart Transplant Recipients Completed
  6. Phase 4 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed
Show 22 more trials
  1. Phase 3 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed
  2. Phase 3 Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed
  3. Phase 3 SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) Completed
  4. Phase 3 SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide Completed
  5. Phase 3 PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study Completed
  6. Phase 3 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Completed
  7. Phase 3 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed
  8. Phase 2 Daptomycin in Treating Neutropenia and Fever in Patients With Cancer Completed
  9. Phase 2 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed
  10. Phase 2 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Completed
  11. Phase 2 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed
  12. Phase 2 Decitabine for High-Risk Sickle Cell Disease Completed
  13. Phase 2 Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed
  14. Phase 2 A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement Completed
  15. Phase 2 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia Completed
  16. Phase 2 Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer Completed
  17. Phase 2 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia Completed
  18. Phase 1 AMD 3100 for Treatment of Myelokathexis Completed
  19. Phase 1 Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed
  20. Phase 1 Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097) Completed
  21. N/A Home Away From Home - Medical Outcomes Completed
  22. N/A The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis compares piperacillin-tazobactam and cefepime in pediatric febrile neutropenia
Pediatrics Meta-analysis
Systematic review and meta-analysis compares piperacillin-tazobactam and cefepime in pediatric febrile neutropenia Two Antibiotics for Fever in Kids: One Works a Day Faster
This systematic review and meta-analysis evaluates piperacillin-tazobactam versus cefepime monotherapy in 470 episodes of pediatric febrile …
When a child on chemotherapy gets a fever, doctors have two main antibiotic choices, and a new analysis of 470 cases shows they work equally…
May 7, 2026
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL
Oncology Meta-analysis
Meta-analysis finds fluoroquinolone prophylaxis reduces febrile neutropenia in pediatric ALL Fluoroquinolone antibiotics lower febrile neutropenia risk in children with acute lymphoblastic leukemia during treatment start
This systematic review and meta-analysis of 991 children with acute lymphoblastic leukemia found that fluoroquinolone prophylaxis reduced fe…
A review of children with acute lymphoblastic leukemia shows fluoroquinolone antibiotics reduce febrile neutropenia risk. This finding sugge…
May 1, 2026
Risk factors for multidrug-resistant organism infections in neutropenic patients
Infectious Disease Cohort
Risk factors for multidrug-resistant organism infections in neutropenic patients Doctors Can Now Predict Deadly Infections in Chemo Patients Before They Strike
This observational cohort study in 391 neutropenic patients identified risk factors for multidrug-resistant organism infections.
This new prediction model could help doctors protect vulnerable patients from life-threatening infections that resist standard treatment.
Frontiers Apr 23, 2026
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
Oncology RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers Apr 16, 2026
FDA Approves Cefepime for Injection and Dextrose Injection (cefepime) for Moderate to Severe Pneumonia and Other Infections
Infectious Disease FDA Approval
FDA Approves Cefepime for Injection and Dextrose Injection (cefepime) for Moderate to Severe Pneumonia and Other Infections The FDA approved a new ready-to-use version of an antibiotic called cefepime for serious infections
The FDA approved cefepime in a dextrose injection formulation for intravenous treatment of moderate to severe pneumonia, febrile neutropenia…
The FDA approved a ready-to-use antibiotic for serious infections like pneumonia and urinary tract infections in hospitalized patients.
FDA Apr 10, 2026